1 |
Aghabozorgi AS, Sharif S, Jafarzadeh-Esfehani R, Vakili S, Abbaszadegan MR. Role of miRNA gene variants in the susceptibility and pharmacogenetics of colorectal cancer. Pharmacogenomics 2021;22:303-18. [PMID: 33733820 DOI: 10.2217/pgs-2020-0159] [Reference Citation Analysis]
|
2 |
Ghafouri-Fard S, Hussen BM, Badrlou E, Abak A, Taheri M. MicroRNAs as important contributors in the pathogenesis of colorectal cancer. Biomed Pharmacother 2021;140:111759. [PMID: 34091180 DOI: 10.1016/j.biopha.2021.111759] [Cited by in Crossref: 2] [Cited by in F6Publishing: 2] [Article Influence: 2.0] [Reference Citation Analysis]
|
3 |
Zhu Y, Lin A, Zheng Y, Xie X, He Q, Zhong W. miR-100 rs1834306 A>G Increases the Risk of Hirschsprung Disease in Southern Chinese Children. Pharmgenomics Pers Med 2020;13:283-8. [PMID: 32848443 DOI: 10.2147/PGPM.S265730] [Reference Citation Analysis]
|
4 |
Ge Y, Shu J, Shi G, Yan F, Li Y, Ding H. miR-100 Suppresses the Proliferation, Invasion, and Migration of Hepatocellular Carcinoma Cells via Targeting CXCR7. J Immunol Res 2021;2021:9920786. [PMID: 34337085 DOI: 10.1155/2021/9920786] [Reference Citation Analysis]
|
5 |
Bignucolo A, Scarabel L, Toffoli G, Cecchin E, De Mattia E. Predicting drug response and toxicity in metastatic colorectal cancer: the role of germline markers. Expert Rev Clin Pharmacol 2022. [PMID: 35829762 DOI: 10.1080/17512433.2022.2101447] [Reference Citation Analysis]
|